Previous close | 8.40 |
Open | 3.50 |
Bid | 5.70 |
Ask | 10.50 |
Strike | 100.00 |
Expiry date | 2024-10-18 |
Day's range | 3.50 - 3.50 |
Contract range | N/A |
Volume | |
Open interest | 9 |
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Consistent with Analyst Projections Amidst Strategic Advancements
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen